21 July 2021
Latham & Watkins Advises Imago BioSciences on its Upsized Initial Public Offering
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Ben Potter Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Rick Kline Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Tess Bloom | Latham & Watkins LLP | Associate | corporate | Not stated |
| Taimi Jacobson | Latham & Watkins LLP | Associate | corporate | Not stated |
| Ajay Sundar | Latham & Watkins LLP | Associate | corporate | Not stated |
| Elizabeth Richards | Latham & Watkins LLP | Partner | healthcare and life sciences regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Counsel | healthcare and life sciences regulatory | Bay Area |
| Leia Gu | Latham & Watkins LLP | Associate | healthcare and life sciences regulatory | Los Angeles |
| Jay Metz | Latham & Watkins LLP | Partner | benefit and compensation | Bay Area |
| Judith Hasko | Latham & Watkins LLP | Partner | intellectual property | Bay Area |
| Stephanie Blij | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Katharine Moir | Latham & Watkins LLP | Partner | tax | Bay Area |
Stated terms
- Stated value
- USD 134m (US$134.4 million)
- What the figure measures
- Issue size
- Client
- Imago BioSciences, Inc.Issuer
- Counterparties
- Not stated